Bei Akademie registrieren
Roche Holding, CH1499059983

Roche Holding stock gains FDA-cleared respiratory test

Published on 11/03/2026 at 18:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Roche Holding stock gains a new US diagnostics milestone after FDA clearance of its customizable RP3 panel. The test supports flexible respiratory testing.

Roche expands respiratory diagnostics

  • The FDA clearance adds a new customizable respiratory testing product to Roche's US diagnostics portfolio.
  • Roche maintained its 2026 outlook while investors assess the commercial potential of the new panel.
  • Laboratories can configure the test for local needs through the cobas eplex system.
Roche Holding, CH1499059983, Illustration mit AI erstellt.
Roche Holding, CH1499059983, Illustration mit AI erstellt.

Roche secured a new US regulatory milestone on Monday, November 2, 2026, when the Food and Drug Administration cleared its cobas eplex respiratory pathogen panel 3. Roche Holding stock traded at 425.30 euros on Lang & Schwarz at 18:02 CET on Tuesday, November 3, 2026. That was 1.42 percent below the 431.43-euro quote reported in the previous article published on November 2.

The regulatory announcement came from Roche Diagnostics. The 510(k) clearance covers the cobas eplex RP3 panel, which is designed for use with Roche's automated cobas eplex system in the United States.

Flexible testing broadens the portfolio

The RP3 panel can detect up to 19 viral and bacterial targets from a single nasopharyngeal sample. Roche said the panel adds Bordetella pertussis detection and updates influenza A and SARS-CoV-2 assays to improve coverage of current and recently circulating strains.

Laboratories can select up to five panel configurations through cobas eplex system software version 3.0 or higher. The automated workflow requires less than one minute of hands-on preparation and delivers qualitative results in under two hours, according to Roche.

Commercial adoption remains the next test

The clearance expands Roche's respiratory diagnostics portfolio and gives laboratories more flexibility during periods of seasonal demand. For investors, the commercial contribution will depend on laboratory adoption, reimbursement and the ability of the new panel to complement Roche's existing testing products.

Investors can follow the real-time quote of Roche Holding stock.

The broader Swiss market can be followed in the SMI market overview.

More news and analyses are available on Roche Holding stock.

Roche Holding AG facts

  • Company: Roche Holding AG
  • ISIN: CH1499059983
  • Trading venue: Lang & Schwarz
  • Price: 425.30 euros at 18:02 CET on November 3, 2026
  • Recent regulatory milestone: FDA 510(k) clearance for the cobas eplex respiratory pathogen panel 3
Disclaimer...
en | CH1499059983 | ROCHE HOLDING | boerse | 70452021 |